Previous 10 | Next 10 |
Search all stock news releases related news releases and press releases from US and Canada Markets.
NEW YORK , Sept. 18, 2020 /PRNewswire/ -- OTC Markets Group Inc. (OTCQX: OTCM), operator of financial markets for over 11,000 U.S. and global securities, today announced Silver Tiger Metals Inc. (TSX-V: SLVR; OTCQX: SLVTF), a silver and gold exploration company operating in ...
Companion diagnostics will be developed to identify patients with NSCLC that harbor ALK fusions and EGFR Exon20 insertion mutations to match patients with appropriate targeted therapies from Takeda Foundation Medicine, Inc. and Takeda Pharmaceuticals USA, Inc., a wholly-owned subsidiar...
− Key Results from Phase 3 ALTA 1L Sub-Analyses Further Support ALUNBRIG’s Strong Intracranial Efficacy and Enhanced Quality of Life in First-Line ALK+ NSCLC − Positive 10-Month Follow-Up Data from Phase 1/2 Trial Reaffirm Mobocertinib’s Previously Report...
Ventas, Inc. (NYSE: VTR) (“Ventas” or the “Company”) today announced that its Board of Directors has declared a quarterly dividend of $0.45 per common share. The dividend will be payable in cash on October 13, 2020 to stockholders of record on October 1, 2020. V...
5-Year Data from Phase 3 SOLO-1 Trial Represents Longest Follow-Up Analysis for Any PARP Inhibitor in First-Line Maintenance Setting Following Response to Platinum-Based Chemotherapy AstraZeneca and Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced p...
TOKYO and BOTHELL, Wash. , Sept. 18, 2020 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa , Ph.D., "Astellas") and Seattle Genetics, Inc . (Nasdaq:SGEN) today announced that a phase 3 trial of PADCEV ® (enfortumab vedotin-ejfv) met ...
- Trial Stopped Early Due to Positive Results at Planned Interim Analysis - - Data Intended to Support Global Registrations and Convert Accelerated to Regular Approval in U.S. - Seattle Genetics, Inc . (Nasdaq:SGEN) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Ke...
TOKYO and BOTHELL, Wash. , Sept. 18, 2020 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa , Ph.D., "Astellas") and Seattle Genetics, Inc . (Nasdaq:SGEN) today announced that a phase 3 trial of PADCEV ® (enfortumab vedotin-ejfv) met ...
SHANGHAI , Sept. 18, 2020 /PRNewswire/ -- Yum China Holdings, Inc. (" Yum China " or the "Company") (NYSE: YUMC and HKEX: 9987), China's largest restaurant company in terms of 2019 system sales, have held a series of activities across China to mark the 30 th anniversary of Pizza Hut i...
STAMFORD, Conn., Sept. 18, 2020 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients with severe rare diseases and cancer, today announced that it has entered into a sponsored...
News, Short Squeeze, Breakout and More Instantly...
Trending Stock
10.72%Change Percent:
Progyny Inc. Company Name:
PGNY Stock Symbol:
NYSE Market: